Exai Bio

Exai Bio’s proprietary RNA-and-AI-powered liquid biopsy platform demonstrates high sensitivity and specificity for early-stage breast and lung cancers. In recent studies, the test detected stage I NSCLC with 95% sensitivity at 90% specificity, stage I breast cancer with 90% sensitivity at the same specificity, and could distinguish invasive from low-grade DCIS. The MRD assay accurately predicted survival post-adjuvant therapy in triple negative breast cancer without requiring tumor tissue sequencing. These results suggest strong potential for earlier diagnosis, improved patient stratification, reduced overtreatment risk in DCIS cases, and broad applicability across multiple solid tumors.